Marie Thibault
Stock Analyst at BTIG
(3.93)
# 671
Out of 4,734 analysts
75
Total ratings
54.29%
Success rate
9.67%
Average return
Main Sectors:
Stocks Rated by Marie Thibault
Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
---|---|---|---|---|---|---|---|
NARI Inari Medical | Downgrades: Neutral | n/a | $79.55 | - | 4 | Jan 8, 2025 | |
EMBC Embecta | Upgrades: Buy | $26 | $18.68 | +39.19% | 2 | Nov 27, 2024 | |
PODD Insulet | Maintains: Buy | $260 → $270 | $275.81 | -2.11% | 4 | Nov 8, 2024 | |
MASI Masimo | Maintains: Buy | $166 → $170 | $172.29 | -1.33% | 3 | Oct 14, 2024 | |
ESTA Establishment Labs Holdings | Maintains: Buy | $62 → $65 | $34.56 | +88.08% | 8 | Oct 14, 2024 | |
BSX Boston Scientific | Maintains: Buy | $84 → $93 | $98.66 | -5.74% | 7 | Oct 14, 2024 | |
HAE Haemonetics | Initiates: Buy | $112 | $73.49 | +52.40% | 1 | Sep 10, 2024 | |
ATRC AtriCure | Maintains: Buy | $58 → $53 | $38.47 | +37.77% | 4 | Jul 31, 2024 | |
DXCM DexCom | Maintains: Buy | $156 → $120 | $84.38 | +42.21% | 7 | Jul 26, 2024 | |
XAIR Beyond Air | Downgrades: Neutral | n/a | $0.42 | - | 2 | Jun 25, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.36 | - | 3 | Oct 6, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $20 | $14.31 | +39.76% | 3 | Aug 16, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $165 → $140 | $108.33 | +29.23% | 7 | Jun 8, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 → $3 | $1.97 | +52.67% | 3 | Mar 29, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 → $125 | $113.48 | +10.15% | 11 | Jan 26, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $7 | $2.24 | +212.50% | 1 | Jun 24, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.46 | - | 3 | Oct 13, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.85 | - | 1 | Jan 21, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 → $6 | $250.97 | -97.61% | 1 | Apr 9, 2020 |
Inari Medical
Jan 8, 2025
Downgrades: Neutral
Price Target: n/a
Current: $79.55
Upside: -
Embecta
Nov 27, 2024
Upgrades: Buy
Price Target: $26
Current: $18.68
Upside: +39.19%
Insulet
Nov 8, 2024
Maintains: Buy
Price Target: $260 → $270
Current: $275.81
Upside: -2.11%
Masimo
Oct 14, 2024
Maintains: Buy
Price Target: $166 → $170
Current: $172.29
Upside: -1.33%
Establishment Labs Holdings
Oct 14, 2024
Maintains: Buy
Price Target: $62 → $65
Current: $34.56
Upside: +88.08%
Boston Scientific
Oct 14, 2024
Maintains: Buy
Price Target: $84 → $93
Current: $98.66
Upside: -5.74%
Haemonetics
Sep 10, 2024
Initiates: Buy
Price Target: $112
Current: $73.49
Upside: +52.40%
AtriCure
Jul 31, 2024
Maintains: Buy
Price Target: $58 → $53
Current: $38.47
Upside: +37.77%
DexCom
Jul 26, 2024
Maintains: Buy
Price Target: $156 → $120
Current: $84.38
Upside: +42.21%
Beyond Air
Jun 25, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.42
Upside: -
Oct 6, 2023
Downgrades: Neutral
Price Target: n/a
Current: $0.36
Upside: -
Aug 16, 2023
Maintains: Buy
Price Target: $19 → $20
Current: $14.31
Upside: +39.76%
Jun 8, 2023
Maintains: Buy
Price Target: $165 → $140
Current: $108.33
Upside: +29.23%
Mar 29, 2023
Maintains: Buy
Price Target: $4 → $3
Current: $1.97
Upside: +52.67%
Jan 26, 2023
Maintains: Buy
Price Target: $120 → $125
Current: $113.48
Upside: +10.15%
Jun 24, 2022
Maintains: Buy
Price Target: $9 → $7
Current: $2.24
Upside: +212.50%
Oct 13, 2021
Downgrades: Neutral
Price Target: n/a
Current: $2.46
Upside: -
Jan 21, 2021
Downgrades: Neutral
Price Target: n/a
Current: $0.85
Upside: -
Apr 9, 2020
Maintains: Buy
Price Target: $11 → $6
Current: $250.97
Upside: -97.61%